ARTICLE | Company News
Sanofi downsizes in cancer R&D
February 12, 2015 2:23 AM UTC
Sanofi (Euronext:SAN; NYSE:SNY) said it will restructure its oncology R&D division and cut about 100 jobs in several North American locations. The oncology division will become an R&D Strategic Therapeutic Unit that reports directly to Sanofi's global R&D organization. Tal Zaks, SVP and head of the global oncology division, will leave the company.
The Genzyme Corp. unit of Sanofi will also narrow its focus to rare diseases and neuroimmunology disorders. ...